Lyell Immunopharma, Inc. (LYEL) income statement
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.89+0.22 (+1.61%)
Close on Nov 18, 2026Market cap $340.38MP/E –Yield –
Lyell Immunopharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -949981.5%
- Net margin
- -920285.2%
- Return on equity, FY2025
- -87.0%
Financial strength
- Current ratio
- 5.36
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 183.1%
Valuation
- P/E ratio
- –
- Price to sales
- 12606.50
- Price to book
- 1.46
- Dividend yield
- –
See a number that looks wrong?